SCHEMBL340105

SCHEMBL340105

CC(C(=O)O)c1cccc(-c2ccccc2)c1Nc1ccccc1C=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 6/20 0.51
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37
MMP14 P50281 1/20 0.37
MMP16 P51512 1/20 0.37
PTGS2 P35354 4/20 0.36
FABP3 P05413 1/20 0.36
FABP4 P15090 1/20 0.36
FABP5 Q01469 1/20 0.36
PTGS1 P23219 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CYP2C9 P11712 2/20 0.36
HPGD P15428 2/20 0.36
FABP2 P12104 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL340339 0.85 CXCL8 (0.39) CXCL8PTGS2LMNAMAPTPDCD1
SCHEMBL339362 0.75 CXCL8 (0.46) CXCL8MMP1MMP2MMP9MMP8
SCHEMBL29243911 0.74 CXCL8 (0.44) CXCL8MMP1MMP2MMP9MMP8
SCHEMBL6131394 0.74 LMNA (0.41) CXCL8MEN1KMT2ACYP2C9TSHR
SCHEMBL341017 0.74 KMT2A (0.45) CXCL8MMP1MMP2MMP9MMP8
SCHEMBL5843818 0.73 LMNA (0.44) CXCL8MMP1MMP2MMP9MMP8
SCHEMBL339351 0.73 PTGER4 (0.48) CXCL8PTGS2FABP3FABP4FABP5
SCHEMBL338541 0.72 MAPT (0.43) CXCL8MMP1MMP2MMP9MMP8
SCHEMBL2393839 0.72 PTGS2 (0.56) CXCL8MMP1MMP2MMP9MMP8
Biphenyl SCHEMBL7876282 0.70 PTGS2 (0.58) CXCL8MMP1MMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181175-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2015-11-10 US disclosed
EP-2387558-B1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2014-08-27 EP disclosed
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2014-06-26 US disclosed
US-8703990-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2014-04-22 US disclosed
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID NOVARTIS AG (CH) 2012-01-19 US disclosed
EP-2387558-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2011-11-23 EP disclosed
US-20110253230-A1 Temperature Sensitive Valve Having Shape Memory Actuator OMNITEK PARTNERS LLC (US) 2011-10-20 US disclosed
WO-2010081410-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 CXCL8 4581/4885MMP1 762/4885MMP2 391/4885
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 CXCL8 4581/4885MMP1 762/4885MMP2 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.